Literature DB >> 14662711

Chronic infusion of bradykinin delays the progression of heart failure and preserves vascular endothelium-mediated vasodilation in conscious dogs.

Daniel Tonduangu1, Luc Hittinger, Bijan Ghaleh, Philippe Le Corvoisier, Lucien Sambin, Stéphane Champagne, Thierry Badoual, Fanny Vincent, Alain Berdeaux, Bertrand Crozatier, Jin Bo Su.   

Abstract

BACKGROUND: This study examined the effects of chronic bradykinin infusion on hemodynamics and myocardial and endothelial functions during the development of heart failure. METHODS AND
RESULTS: Sixteen instrumented dogs were randomized to receive through the left atria either vehicle or bradykinin (1 microg/min) during ventricular pacing (250 bpm, 5 weeks). Hemodynamic and left ventricular (LV) parameters and the vasodilator responses to intravenous acetylcholine (0.3 to 3 microg/kg) and nitroglycerin (1 to 10 microg/kg) were examined in the control and after 3 and 5 weeks of pacing. The expression of endothelial NOS in femoral, carotid, and renal arteries was determined by Western blot analysis. After 3 weeks of pacing, changes in LV diastolic and systolic parameters were significantly lower in bradykinin-treated than vehicle-treated dogs (LV end-diastolic pressure, +10+/-3 versus +19+/-2 mm Hg; time constant of LV isovolumic relaxation, +11+/-2 versus +17+/-1 ms; LV wall thickening, -33+/-18% versus -75+/-9%; and cardiac output, -16+/-6% versus -32+/-6%; all P<0.05). Compared with vehicle-treated dogs, bradykinin-treated dogs had a reduced rightward shift of the diastolic LV pressure-diameter relation and a reduced diastolic LV wall stress. Similar trends were observed after 5 weeks. The vasodilator response to nitroglycerin was preserved in both groups. The response to acetylcholine was blunted in vehicle-treated but preserved in bradykinin-treated dogs. Vascular endothelial NOS expression decreased in vehicle-treated but was preserved in bradykinin-treated dogs.
CONCLUSIONS: In conscious dogs, chronic bradykinin infusion delays the heart failure progression by preserving LV diastolic and systolic functions and by preserving vascular endothelial function.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14662711     DOI: 10.1161/01.CIR.0000105726.89770.35

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  5 in total

1.  Vascular endothelial dysfunction in Duchenne muscular dystrophy is restored by bradykinin through upregulation of eNOS and nNOS.

Authors:  Hubert Dabiré; Inès Barthélémy; Nicolas Blanchard-Gutton; Lucien Sambin; Carolina Carlos Sampedrano; Vassiliki Gouni; Yves Unterfinger; Pablo Aguilar; Jean-Laurent Thibaud; Bijan Ghaleh; Alain Bizé; Jean-Louis Pouchelon; Stéphane Blot; Alain Berdeaux; Luc Hittinger; Valérie Chetboul; Jin Bo Su
Journal:  Basic Res Cardiol       Date:  2011-12-23       Impact factor: 17.165

Review 2.  Vascular endothelial dysfunction and pharmacological treatment.

Authors:  Jin Bo Su
Journal:  World J Cardiol       Date:  2015-11-26

Review 3.  The vital role for nitric oxide in intraocular pressure homeostasis.

Authors:  Ester Reina-Torres; Michael L De Ieso; Louis R Pasquale; Michael Madekurozwa; Joseph van Batenburg-Sherwood; Darryl R Overby; W Daniel Stamer
Journal:  Prog Retin Eye Res       Date:  2020-11-28       Impact factor: 21.198

4.  Crossing the chasm: caution for use of angiotensin receptor-neprilysin inhibition in patients with cardiogenic shock- a case report.

Authors:  Loai Almazroa; Vesna Mihajlovic; Patrick R Lawler; Adriana Luk
Journal:  Eur Heart J Case Rep       Date:  2020-10-19

Review 5.  Management of Chronic Congestive Heart Failure Caused by Myxomatous Mitral Valve Disease in Dogs: A Narrative Review from 1970 to 2020.

Authors:  Mara Bagardi; Viola Zamboni; Chiara Locatelli; Alberto Galizzi; Sara Ghilardi; Paola G Brambilla
Journal:  Animals (Basel)       Date:  2022-01-16       Impact factor: 2.752

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.